Rheumatology Therapeutics Market Set to Expand from $40.45 Billion in 2023 to $51.42 Billion in 2028 - Global Long-term Forecast to 2033
October 10, 2024 11:23 ET
|
Research and Markets
Dublin, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The "Rheumatology Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global rheumatology therapeutics market...
Plaque Psoriasis Drug Forecast and Market Analysis to 2030: Focus on SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279
September 30, 2024 09:37 ET
|
Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This...
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
April 16, 2024 14:06 ET
|
Spherix Global Insights
EXTON, PA, April 16, 2024 (GLOBE NEWSWIRE) -- In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA),...
COSENTYX (Secukinumab) Market Analysis and Outlook 2019-2032: Mechanism, Dosage, Research, Sales, Regulatory Milestones, Patents, SWOT Analysis
April 02, 2024 11:47 ET
|
Research and Markets
Dublin, April 02, 2024 (GLOBE NEWSWIRE) -- The "COSENTYX Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
January 22, 2024 10:47 ET
|
Spherix Global Insights
EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld their...
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
January 10, 2024 15:58 ET
|
Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
October 03, 2023 13:57 ET
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...
Insights on the Ankylosing Spondylitis Global Market to 2030 - Rise in Number of Hospitals and Diagnostic Centers is Driving Growth
May 05, 2022 08:08 ET
|
Research and Markets
Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Market by Drug Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been...
Global Ankylosing Spondylitis Market Outlook Report 2019-2027: Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities
December 21, 2020 10:53 ET
|
Research and Markets
Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. Global Ankylosing Spondylitis...
Global Ankylosing Spondylitis Market Outlook to 2027: High Treatment Cost and Lack of Skilled Surgeons and Physiotherapists are Hampering Market Growth
November 04, 2020 04:43 ET
|
Research and Markets
Dublin, Nov. 04, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. Global Ankylosing Spondylitis...